Company Essex Bio-Technology Limited

1061

KYG312371035

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 01:34:52 2025-06-18 am EDT			5-day change	1st Jan Change
5.000 ^HKD	+6.38%		+0.40%	+69.05%

Apr. 03	Phase 3 Study for Henlius, Essex's Wet Age-Related Macular Degeneration Drug Reaches Primary Endpoint; Essex Shares Up 11%	MT
Apr. 02	Essex Bio-Technology Limited Announces Phase 3 Clinical Study of the Anti-Vegf Ophthalmic Injection Bio-Pharmaceutical Product	CI

Business description: Essex Bio-Technology Limited

Essex Bio-Technology Ltd is an investment holding company principally engaged in the manufacture and sales of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Company develops biopharmaceutical drugs based on recombinant deoxyribonucleic acid (DNA) technology. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin. The Company operates through two segments. The Surgical segment is engaged in the manufacture and sale of Beifuji spray, Beifuji lyophilised powder and Beifuxin gel. The Ophthalmology segment is engaged in the manufacture and sale of Beifushu eye drops, Beifushu eye gel and Beifushu unit-dose eye drops.

Number of employees: 1,450

Sales by Activity: Essex Bio-Technology Limited

Fiscal Period: December	2020	2021	2022	2023	2024
Surgical	559M	964M	764M	953M	880M
Ophthalmology	419M	673M	554M	753M	771M
Provision of Services	-	-	-	-	18.42M

See all business segments

Geographical breakdown of sales: Essex Bio-Technology Limited

Fiscal Period: December	2020	2021	2022	2023	2024
People's Republic of China (The PRC)	978M	1.64B	1.32B	1.71B	1.66B
Overseas	-	-	-	-	7.52M

See all geographic segments

Executive Committee: Essex Bio-Technology Limited

Manager	Title	Age	Since
Hai Zhou Fang CEO	Chief Executive Officer	59	2000-07-30
Qi Xue CTO	Chief Tech/Sci/R&D Officer	64	2018-04-08
Hian Leng Ngiam PRN	Corporate Officer/Principal	40	2017-12-31
Lai Man Yau AUD	Comptroller/Controller/Auditor	61	2020-09-18

See ESSEX BIO-TECHNOLOGY LIMITED governance

Composition of the Board of Directors: Essex Bio-Technology Limited

Director	Title	Age	Since
Hai Zhou Fang BRD	Director/Board Member	59	2000-07-30
Chi Ying Fung BRD	Director/Board Member	70	2001-06-12
Mee Mooi Yeow BRD	Director/Board Member	62	2004-09-29
Mia Je Ngiam CHM	Chairman	70	1999-01-31
Lai Man Yau BRD	Director/Board Member	61	2020-09-18
Hian Leng Ngiam BRD	Director/Board Member	40	2020-09-18
Man Sing Yan BRD	Director/Board Member	67	2023-06-08

Composition of the Board of Directors

Shareholders: Essex Bio-Technology Limited

Name	Equities	%	Valuation
Mia Je Ngiam 27.15 %	153,945,667	27.15 %	102 M $
Essex Investment (Singapore) Pte Ltd. 1.176 %	6,666,667	1.176 %	4 M $
Hai Zhou Fang 0.9248 %	5,244,300	0.9248 %	3 M $
Pheim Asset Management Sdn. Bhd. 0.6752 %	3,828,900	0.6752 %	3 M $
Hian Leng Ngiam 0.3596 %	2,039,000	0.3596 %	1 M $

List of ESSEX BIO-TECHNOLOGY LIMITED shareholders

Company details: Essex Bio-Technology Limited

Essex Bio-Technology Ltd.

West Tower, Shun Tak Centre 168-200 Connaught Road

, Hong Kong

http://www.essexbio.com

address Essex Bio-Technology Limited(1061)

Biopharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ESSEX BIO-TECHNOLOGY LIMITED	+1.70%	-3.43%	+94.31%	+37.36%	360M
CSL LIMITED	+0.21%	-1.91%	-17.08%	-7.43%	75.66B
SAMSUNG BIOLOGICS CO.,LTD.	-0.39%	+1.50%	+37.72%	+28.48%	53.22B
UCB	-2.35%	-1.46%	+15.27%	+100.90%	35.67B
BIOGEN INC.	-3.42%	-5.66%	-44.11%	-33.92%	19.2B
INNOVENT BIOLOGICS, INC.	-0.52%	-3.04%	+101.31%	+199.80%	16.89B
ALTEOGEN INC.	+5.19%	+10.04%	+53.02%	+952.11%	15.96B
INTRA-CELLULAR THERAPIES, INC.	-0.04%	-.--%	+94.58%	+133.27%	14.02B
INCYTE CORPORATION	-3.38%	-1.55%	+9.76%	+1.13%	13.79B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-2.20%	-12.17%	-4.63%	-32.48%	11.22B
Average	-0.55%	-0.84%	+34.02%	+137.92%	25.6B
Weighted average by Cap.	-0.64%	-1.42%	+17.24%	+93.79%